Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria

A Phase II/III Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of ICP-332 in Moderate to Severe Chronic Spontaneous Urticaria Subjects Inadequately Controlled by Second Generation H1-antihistamines

The purpose of this study is to compare the efficacy and safety of ICP-332 in moderate to severe chronic spontaneous urticaria subjects inadequately controlled by second generation H1-antihistamines

Inclusion Criteria:

• 1. Men and women aged 18 to 75 years.
• 2. Diagnosis of CSU inadequately controlled by second generation H1-antihistamines.
• 3. CSU duration for ≥ 6 months prior to randomization.
• 4. Before initiating any screening or study-specific procedures, the subject must voluntarily sign the informed consent form.

Exclusion Criteria:

• 1. Having the other medical conditions related to CSU or other skin diseases/conditions.
• 2. Potential medical conditions or issues.
• 3. Pregnant female subjects or lactating female subjects.
• 4. The investigator determines that the subject is unsuitable for participating in this study for any reason.